Viola Zhu


Assistant Clinical Professor, Medicine
School of Medicine

MD PhD

Phone: (714) 456-8000
Email: zhuvw@uci.edu

University of California, Irvine
101 The City Dr S
Mail Code: 4061
Orange, CA 92868
Research Interests
Lung cancer
Publications
1. Hoover DJ, Zhu V, Chen R, Briley K Jr, Rameshwar P, Cohen S, Coffman FD. Expression of the chitinase family glycoprotein YKL-40 in undifferentiated, differentiated and trans-differentiated mesenchymal stem cells. PLoS One 2013;8:e62491. PMID: 23671604

2. Zhu V, de las Morenas A, Janicek M, Hartshorn M. Hypercalcemia from metastatic pancreatic neuroendocrine tumor secreting 1,25-dihydroxyvitamin D. J Gastrointest Oncol 2014;5:E84-87. PMID: 25083313

3. Zhu VW, Upadhyay D, Schrock AB, Gowen K, Ali SM, Ou Sh. TPD52L1-ROS1, a new ROS1 fusion variant in lung adenosquamous cell carcinoma identified by comprehensive genomic profiling. Lung Cancer 2016;97:48-50. PMID: 227237027

4. Zhu VW, Ou SH. ASCEND-2: a canary in a coal mine for descending to second-line treatment for ALK-rearranged non-small cell lung cancer. Trans Lung Cancer Res 2016;5:660-664. PMID: 28149759

5. Ou SH, Young L, Schrock AB, Johnson A, Klempner SJ, Zhu VW, Miller VA, Ali SJ. Emergence of preexisting MET Y1230C mutation as a resistance mechanism to crizotinib in NSCLC with MET exon14 skipping. J Thorac Oncol 2017;12:137-140. PMID: 27666659

6. Reungwetwattanaa T, Liang Y, Zhu V, Ou SH. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: the Why, the How, the Who, the Unknown, and the Inevitable. Lung Cancer 2017;103:27-37. PMID: 28024693

7. Ou SH, Lee TK, Young L, Pavlick D, Schrock AB, Ali SM, Zhu VW, Milliken J, Gitlitz BJ. Dual occurrence of ALK G1202R solvent front mutation and small cell lung cancer transformation as resistance mechanisms to second generation ALK inhibitors without exposure to crizotinib. Pitfall of solely relying on liquid re-biopsy? Lung Cancer 2017;106:110-4. PMID: 28285684

8. Zhu VW, Ou SH. Safety of alectinib for the treatment of ALK-rearranged non-small cell lung cancer. Expert Opin Drug Saf 2017;16:509-14. PMID: 28276856

9. Zhu VW, Hinduja S, Knezevich CR, Silveira WR, DeLozier CD. A rare case of choroid plexus carcinoma that led to the diagnosis of Lynch syndrome (hereditary nonpolyposis colorectal cancer) spectrum. Clin Neurol Neurosurg 2017;158:46-8. PMID: 28460341

10. Ou SH, Cui J, Schrock AB, Goldberg ME, Zhu VW, Albacker L, Stephens PJ, Miller VA, Ali SM. Emergence of novel and dominant acquired EGFR solvent-front mutations at Gly796 (G769S/R) together with C797S/R and L792F/H mutations in one EGFR (L858R/T790M) NSCLC patient who progressed on osimertinib. Lung Cancer 2017;108:228-31. PMID: 28625641

11. Zhu VW, Cui JJ, Fernandez-Rocha M, Schrock AB, Ali SM, Ou SH. Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinib. Lung Cancer 2017;110:32-4. PMID: 28676215
Professional Societies
American Society of Clinical Oncology
International Association for the Study of Lung Cancer
Graduate Programs
Internal Medicine

Hematology and Oncology (IM)

Last updated
07/17/2017